Meeting
2023 ASCO Genitourinary Cancers Symposium
Spatial immunophenotypes of distant metastases and response to immune checkpoint inhibition.
Authors
Franziska Erlmeier
Institute of Pathology, TU Munich, Munich, Germany
Franziska Erlmeier , Niklas Klümper , Pamela Strissel , Reiner Strick , Danijel Sikic , Veronika Bahlinger , Johannes Breyer , Manuel Ritter , Christian Bolenz , Florian Roghmann , Philipp Erben , Kristina Schwamborn , Ralph M. Wirtz , Thomas Horn , Bernd Wullich , Michael Hölzel , Arndt Hartmann , Jürgen E. Gschwend , Wilko Weichert , Markus Eckstein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 538)
DOI
10.1200/JCO.2023.41.6_suppl.538
Abstract #
538
Poster Bd #
M1
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
US real-world first-line (1L) treatment patterns and outcomes for patients with metastatic urothelial carcinoma (mUC) following maintenance avelumab approval.
First Author: Haojie Li
Poster
2022 ASCO Annual Meeting
A phase Ib study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).
First Author: Yunpeng Yang
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Prevalence of PD-L1 expression in first-line (1L) locally advanced/unresectable or metastatic urothelial carcinoma (UC).
First Author: Petros Grivas
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Updated pooled analyses of first-line anti-PD1/PD-L1 inhibitors plus chemotherapy in advanced esophageal squamous cell carcinoma.
First Author: Maysa Vilbert